David Rolfe's EW Position Overview
David Rolfe (via Wedgewood Partners INC) currently holds 180,882 shares of Edwards Lifesciences Corporation (EW) worth $15.42 M, representing 2.88% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 36 quarters.
Based on 13F filings, David Rolfe has maintained a strategic position in EW, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2017, adding 1.45 M shares. Largest reduction occurred in Q2 2017, reducing 827,172 shares.
Analysis based on 13F filings available since 2013 Q2
David Rolfe's Edwards Lifesciences Corporation (EW) Holding Value Over Time
Track share changes against reported price movement
Quarterly Edwards Lifesciences Corporation (EW) Trades by David Rolfe
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -3,819 | Reduce 2.07% | 180,882 | $85.25 |
| Q3 2025 | +6,667 | Add 3.74% | 184,701 | $77.77 |
| Q2 2025 | -13,784 | Reduce 7.19% | 178,034 | $80.09 |
| Q1 2025 | -147,618 | Reduce 43.49% | 191,818 | $76.75 |
| Q4 2024 | -19,821 | Reduce 5.52% | 339,436 | $74.03 |
| Q3 2024 | +4,830 | Add 1.36% | 359,257 | $66.52 |
| Q2 2024 | +108,976 | Add 44.40% | 354,427 | $65.54 |
| Q1 2024 | -5,201 | Reduce 2.07% | 245,451 | $90.16 |
| Q4 2023 | +56,855 | Add 29.34% | 250,652 | $86.26 |
| Q3 2023 | -121,376 | Reduce 38.51% | 193,797 | $69.28 |
| Q2 2023 | -14,897 | Reduce 4.51% | 315,173 | $94.33 |
| Q1 2023 | -3,690 | Reduce 1.11% | 330,070 | $0.08 |
| Q4 2022 | +2,133 | Add 0.64% | 333,760 | $0.07 |
| Q3 2022 | -9,062 | Reduce 2.66% | 331,627 | $82.63 |
| Q2 2022 | -17,531 | Reduce 4.89% | 340,689 | $95.09 |
| Q1 2022 | +5,071 | Add 1.44% | 358,220 | $117.72 |
| Q4 2021 | -119,478 | Reduce 25.28% | 353,149 | $129.55 |
| Q3 2021 | -10,909 | Reduce 2.26% | 472,627 | $113.21 |
| Q2 2021 | -30,352 | Reduce 5.91% | 483,536 | $103.57 |
| Q1 2021 | -81,068 | Reduce 13.63% | 513,888 | $83.64 |
| Q4 2020 | -36,762 | Reduce 5.82% | 594,956 | $91.23 |
| Q3 2020 | -36,824 | Reduce 5.51% | 631,718 | $79.82 |
| Q2 2020 | -43,058 | Reduce 6.05% | 668,542 | $69.11 |
| Q1 2020 | -410,586 | Reduce 36.59% | 711,600 | $62.87 |
| Q4 2019 | -314,181 | Reduce 21.87% | 1.12 M | $77.76 |
| Q3 2019 | -124,512 | Reduce 7.98% | 1.44 M | $73.30 |
| Q2 2019 | -421,578 | Reduce 21.27% | 1.56 M | $61.58 |
| Q1 2019 | -480,939 | Reduce 19.52% | 1.98 M | $63.78 |
| Q4 2018 | +6,516 | Add 0.27% | 2.46 M | $51.06 |
| Q3 2018 | -217,350 | Reduce 8.13% | 2.46 M | $58.03 |
| Q2 2018 | -722,793 | Reduce 21.28% | 2.67 M | $48.52 |
| Q1 2018 | -622,263 | Reduce 15.48% | 3.4 M | $46.51 |
| Q4 2017 | -9,855 | Reduce 0.24% | 4.02 M | $37.57 |
| Q3 2017 | +1.45 M | Add 55.92% | 4.03 M | $36.44 |
| Q2 2017 | -827,172 | Reduce 24.25% | 2.58 M | $39.41 |
| Q1 2017 | +3.41 M | New Buy | 3.41 M | $31.36 |
David Rolfe's Edwards Lifesciences Corporation Investment FAQs
David Rolfe first purchased Edwards Lifesciences Corporation (EW) in Q1 2017, acquiring 3,411,216 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
David Rolfe has held Edwards Lifesciences Corporation (EW) for 36 quarters since Q1 2017.
David Rolfe's largest addition to Edwards Lifesciences Corporation (EW) was in Q1 2017, adding 3,411,216 shares worth $106.96 M.
According to the latest 13F filing for Q4 2025, David Rolfe's firm, Wedgewood Partners INC, owns 180,882 shares of Edwards Lifesciences Corporation (EW), valued at approximately $15.42 M.
As of the Q4 2025 filing, Edwards Lifesciences Corporation (EW) represents approximately 2.88% of David Rolfe's publicly disclosed stock portfolio, making it one of their key holdings.
David Rolfe's peak holding in Edwards Lifesciences Corporation (EW) was 4,029,141 shares, as reported at the end of Q3 2017.